Zoledronic Acid Versus Placebo in the Treatment of Skeletal Metastases in Patients With Lung Cancer and Other Solid Tumors: A Phase III, Double-Blind, Randomized Trial—The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group
Top Cited Papers
- 15 August 2003
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (16) , 3150-3157
- https://doi.org/10.1200/jco.2003.04.105
Abstract
Purpose: To assess the efficacy and safety of zoledronic acid in patients with bone metastases secondary to solid tumors other than breast or prostate cancer.Keywords
This publication has 13 references indexed in Scilit:
- The New Bisphosphonate, Zometa®(Zoledronic Acid), Decreases Skeletal Complications in Both Osteolytic and Osteoblastic Lesions: A Comparison to PamidronateCancer Investigation, 2002
- Methodology for treatment evaluation in patients with cancer metastatic to bone.JNCI Journal of the National Cancer Institute, 2001
- Zoledronic acid reduces skeletal-related events in patients with osteolytic metastasesCancer, 2001
- Zoledronic Acid Is Superior to Pamidronate in the Treatment of Hypercalcemia of Malignancy: A Pooled Analysis of Two Randomized, Controlled Clinical TrialsJournal of Clinical Oncology, 2001
- Survival analysis for recurrent event data: an application to childhood infectious diseasesStatistics in Medicine, 2000
- Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review.Journal of Clinical Oncology, 1998
- Skeletal complications of malignancyCancer, 1997
- USE OF THE WEI-LIN-WEISSFELD METHOD FOR THE ANALYSIS OF A RECURRING AND A TERMINATING EVENTStatistics in Medicine, 1997
- Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple MyelomaNew England Journal of Medicine, 1996
- Cox's Regression Model for Counting Processes: A Large Sample StudyThe Annals of Statistics, 1982